These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 10707569)
1. [Diabetes mellitus]. Kawano M; Kanazawa Y Nihon Rinsho; 2000 Feb; 58(2):421-5. PubMed ID: 10707569 [TBL] [Abstract][Full Text] [Related]
2. [The development of thiazolidinedione drugs as anti-diabetic agents]. Kuzuya T Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559 [TBL] [Abstract][Full Text] [Related]
3. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Scheen AJ; Lefèbvre PJ Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug]. Toyota T Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410 [TBL] [Abstract][Full Text] [Related]
8. Troglitazone in type II diabetes mellitus. Sparano N; Seaton TL Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione hepatotoxicity: a class effect? Tolman KG Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes]. Kitaoka H Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035 [No Abstract] [Full Text] [Related]
11. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Sauer WH; Cappola AR; Berlin JA; Kimmel SE Am J Cardiol; 2006 Mar; 97(5):651-4. PubMed ID: 16490431 [TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613 [TBL] [Abstract][Full Text] [Related]
14. The use of insulin secretagogues in the treatment of type 2 diabetes. Luna B; Hughes AT; Feinglos MN Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467 [TBL] [Abstract][Full Text] [Related]